Sharp Memorial Hospital

1. Daiichi Sankyo Inc. $3,248,277 2,141 payments
2. Novartis Pharmaceuticals Corporation $1,975,997 12 payments
3. Daiichi Sankyo Company LTD $1,269,681 52 payments
4. Incyte Corporation $735,689 274 payments
5. Clovis Oncology, Inc. $620,467 105 payments
6. Octapharma USA, Inc. $547,925 4 payments
7. Pfizer Inc. $539,658 263 payments
8. GlaxoSmithKline, LLC. $180,357 19 payments
9. EMD Serono, Inc. $172,182 41 payments
10. AstraZeneca Pharmaceuticals LP $160,584 17 payments

1. Ribociclib Standard Endocrine Therapy in Patients With HR Her2 Early BC at High Amp Intermediate Risk for Recurrence $1,975,997 12 payments
2. Ds8201-A-J101 $1,709,475 363 payments
3. Ds8201-A-U201 $732,112 968 payments
4. Ds8201-A-J101 $620,489 165 payments
5. Ds8201-A-U301 $532,936 294 payments
6. A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) $459,035 62 payments
7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma $382,440 22 payments
8. Study name not reported $347,209 23 payments
9. Gam10-10 $331,000 2 payments
10. Gam10-10 $216,925 2 payments

1. Professional salary support $14,704 6 payments
2. Non-patient care $3,500 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.